Recently, CD8 + T-cells deficient in both PD-1 and LAG-3 were shown to exhibit enhanced tumor clearance in a mouse model of melanoma due to increased secretion of IFN-γ [55], and a combination of relatlimab and nivolumab affected the differentiation of CD8 + T-cells by enhancing responses to TCR receptor and IFN-γ signaling, which was associated with enhanced effector functions of T-cells [56]. This evidence concerns the gene CD8A and neoplasm.